PharmaRadar360

PharmaRadar360

Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

40,350 stories, page 374 of 673

Advanced search
🌍discoverynews.google.comTier 3 · Aggregated media

Oncolytics Biotech (NASDAQ:ONCY) Trading Up 0.2% - Time to Buy?

MarketBeatOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Mumbai’s elite clubs lose FSSAI licences after FDA crackdown

Hotelier IndiaOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Bombay HC slams FDA over "untrue" clean chit to Mantralaya canteen after lawyers' surprise inspection uncovers hygiene lapses

Bar and BenchOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Novo Nordisk's August Reckoning: Courtroom Battles and a Failed Heart Drug Converge

AD HOC NEWSOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

CREATE medicines expands targeted in vivo CAR platform through strategic research collaboration and exclusive license agreement with Monash University

Monash UniversityOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Daily Brief Health Care: Moleculin Biotech , Attovia Therapeutics, BioStem Technologies , Harbin Yuyantang Traditional Chinese Medicine Outpatient Group, Braveheart Bio, Vogenx, Apnimed and more

SmartkarmaOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

IPO Databook: Moleculin Biotech (MBRX US) - Jul 2026

SmartkarmaOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Price to sales forward of Samil Pharmaceutical Co., Ltd. – KRX:000520

TradingViewOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

BlackRock, Inc. Trims Alumis Inc (ALMS) Stake Amid Biotech's Met

GuruFocusOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

H.C. Wainwright reiterates Inhibikase stock rating on FDA orphan drug status

Investing.com UKOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Novo Nordisk misses key heart outcomes in Phase 3, shares sink 10% - CHOSUNBIZ

ChosunbizOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

B.Riley initiates 4D Molecular Therapeutics stock coverage with buy rating

Investing.com UKOriginal source
🌍Industrymonashhealth.orgTier 1 · Company source

Transforming Tracheostomy Education – From Local Innovation to National Impact

Monash HealthOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Medicines, Misleading Ads On Tukaram Mundhe's Radar? Maharashtra FDA Chief Says...

NDTV ProfitOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

FDA panel backs unapproved peptides despite safety concerns

Drug Discovery NewsOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Chong Kun Dang’s CKD-339 Enters Phase 3 in South Korea for Patients Uncontrolled on Monotherapy

코메디닷컴Original source
🌍discoverynews.google.comTier 3 · Aggregated media

West Pharmaceutical Services (WST) Raised Guidance, Is It Still 16% Undervalued?

simplywall.stOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Doctors warn against 'most powerful weight-loss jab ever as users exploit legal loophole

LADbibleOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Actinogen Medical advances pivotal XanaMIA trial towards November readout - ICYMI

Proactive financial newsOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Editorial] Indigenous-led cancer control

Lancet OncologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Corrections] Correction to Lancet Oncol 2026; 27: 452–60

Lancet OncologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Correspondence] Risks of modelling cancer outcomes when no data exist – Authors' reply

Lancet OncologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Comment] Cretostimogene grenadenorepvec: promise beyond response

Lancet OncologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Correspondence] Risks of modelling cancer outcomes when no data exist

Lancet OncologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Comment] Chest wall radiotherapy in SUPREMO: a quality-of-life perspective

Lancet OncologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Comment] Chemoradiotherapy intensification in rectal cancer: lessons from the ARISTOTLE trial

Lancet OncologyOriginal source
🇺🇸Researchreporter.nih.govTier 2 · Direct publisher

NIH award: A comprehensive investigation of Pseudomonas quorum sensing regulatory relationships and the consequences on quorum sensing inhibitors in complex communities

Recipient: MASSACHUSETTS GENERAL HOSPITAL. Award amount: 389004.

NIH RePORTEROriginal source
🇺🇸Researchreporter.nih.govTier 2 · Direct publisher

NIH award: Recruitment and Retention for Alzheimer's Disease Diversity Genetic Cohorts in the ADSP (READD-ADSP)

Recipient: UNIVERSITY OF MIAMI SCHOOL OF MEDICINE. Award amount: 42995.

NIH RePORTEROriginal source
🇺🇸Researchreporter.nih.govTier 2 · Direct publisher

NIH award: Longitudinal study of metal mixtures and the developmental origins of adolescent risk-taking

Recipient: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI. Award amount: 155074.

NIH RePORTEROriginal source
🇺🇸Researchreporter.nih.govTier 2 · Direct publisher

NIH award: I4C 2.0: Immunotherapy for Cure

Recipient: BETH ISRAEL DEACONESS MEDICAL CENTER. Award amount: 4653643.

NIH RePORTEROriginal source
🇺🇸Researchreporter.nih.govTier 2 · Direct publisher

NIH award: Persistence of HIV-specific B cells after long-term antiretroviral therapy in early treated Thai children

Recipient: OREGON HEALTH & SCIENCE UNIVERSITY. Award amount: 236444.

NIH RePORTEROriginal source
🇺🇸Researchreporter.nih.govTier 2 · Direct publisher

NIH award: Structure-based Sieve Analysis to Understand the Impact of Antibody-Mediated Immunity

Recipient: HENRY M. JACKSON FDN FOR THE ADV MIL/MED. Award amount: 317272.

NIH RePORTEROriginal source
🇺🇸Researchreporter.nih.govTier 2 · Direct publisher

NIH award: A Pseudovirus Nanoparticle-Based Mpox Vaccine for Oral Immunization

Recipient: CINCINNATI CHILDRENS HOSP MED CTR. Award amount: 243000.

NIH RePORTEROriginal source
🇺🇸Researchreporter.nih.govTier 2 · Direct publisher

NIH award: Characterizing the impact of Hlb expression on the ability of MRSA to evade human PMN responses

Recipient: MONTANA STATE UNIVERSITY - BOZEMAN. Award amount: 217500.

NIH RePORTEROriginal source
🇺🇸Researchreporter.nih.govTier 2 · Direct publisher

NIH award: Enhancing glioblastoma virotherapy with a bioluminescent Zika virus NS5 sensor and integrated gene circuit

Recipient: CENTRAL MICHIGAN UNIVERSITY. Award amount: 144641.

NIH RePORTEROriginal source
🇺🇸Researchreporter.nih.govTier 2 · Direct publisher

NIH award: CTSA Predoctoral T32 at the University of Florida: CTS Team Training

Recipient: UNIVERSITY OF FLORIDA. Award amount: 297919.

NIH RePORTEROriginal source
🇺🇸Researchreporter.nih.govTier 2 · Direct publisher

NIH award: Transcriptional regulation of chamber selective gene expression

Recipient: BOSTON CHILDREN'S HOSPITAL. Award amount: 809323.

NIH RePORTEROriginal source
🇺🇸Researchreporter.nih.govTier 2 · Direct publisher

NIH award: IL21R signaling in CD4 T cells converts transient KRASi responses to long term remissions

Recipient: DANA-FARBER CANCER INST. Award amount: 643414.

NIH RePORTEROriginal source
🇺🇸Researchreporter.nih.govTier 2 · Direct publisher

NIH award: Building a unified framework for understanding bacterial gene regulation and chromosomal architecture

Recipient: UNIVERSITY OF MICHIGAN AT ANN ARBOR. Award amount: 407009.

NIH RePORTEROriginal source
🇺🇸Researchreporter.nih.govTier 2 · Direct publisher

NIH award: Unveiling Functional Roles of Apical Surface Interactions Between Opposing Cell Layers

Recipient: UNIVERSITY OF WASHINGTON. Award amount: 441250.

NIH RePORTEROriginal source
🇺🇸Researchreporter.nih.govTier 2 · Direct publisher

NIH award: Engineering Immunostimulatory Spherical Nucleic Acids for B cell adoptive therapy

Recipient: NORTHWESTERN UNIVERSITY. Award amount: 660525.

NIH RePORTEROriginal source
🇺🇸Researchreporter.nih.govTier 2 · Direct publisher

NIH award: FlyBand-Peds: Evaluating Biomechanics of Integrated Exoskeleton Footwear for Pediatric Charcot-Marie-Tooth Disease

Recipient: RESULTS GROUP. Award amount: 305904.

NIH RePORTEROriginal source
🇺🇸Researchreporter.nih.govTier 2 · Direct publisher

NIH award: A Designed Host Defense Peptide to Prevent Burn Infections

Recipient: RIPTIDE BIOSCIENCE, INC.. Award amount: 1000000.

NIH RePORTEROriginal source
🇺🇸Researchreporter.nih.govTier 2 · Direct publisher

NIH award: Investigating the origin and functional impact of "hidden" structural variants in rare genetic diseases

Recipient: PACIFIC NORTHWEST RESEARCH INSTITUTE. Award amount: 1231446.

NIH RePORTEROriginal source
🇺🇸Regulatoryopen.fda.govTier 1 · Regulatory source

Drug label update: Potassium Chloride

Official structured record identifier: f9965f73-e189-423f-bd10-c4a0ed12b485.

openFDA Drug LabelsOriginal source
🇺🇸Regulatoryopen.fda.govTier 1 · Regulatory source

Drug label update: Dexamethasone sodium phosphate

Official structured record identifier: c6f2563b-5a39-48bf-bcfe-71dd417bd970.

openFDA Drug LabelsOriginal source
🇺🇸Regulatoryopen.fda.govTier 1 · Regulatory source

Drug label update: Ibuprofen and famotidine

Official structured record identifier: 9f5de6af-e555-4efd-a3ed-b72c34c051b6.

openFDA Drug LabelsOriginal source
🇺🇸Regulatoryopen.fda.govTier 1 · Regulatory source

Drug label update: unspecified product

Official structured record identifier: 31be21c3-984b-de50-e063-6394a90a86ff.

openFDA Drug LabelsOriginal source
🇺🇸Regulatoryopen.fda.govTier 1 · Regulatory source

Drug label update: CAFFEINE CITRATE

Official structured record identifier: 279a43b8-9ff5-4792-ac19-441f3fa49269.

openFDA Drug LabelsOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

Exposure-Response Relationship of Dostarlimab in Primary Advanced/Recurrent Endometrial Cancer: Results From Interim Analysis 2 of Part 1 of the RUBY Trial.

Europe PMCOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

Open-Label, Balanced, Randomized, Single-Dose, Three-Treatment, Three-Sequence, Three-Period, Three-Way Crossover Oral Bioequivalence Study of Desmopressin Acetate Oral Solution.

Europe PMCOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

The Economics Of Orphan Blockbuster Drug Development.

Europe PMCOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

Antithrombotic strategy according to age in patients with atrial fibrillation and drug-eluting stents: a post hoc analysis of the ADAPT AF-DES randomised trial.

Europe PMCOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

Comment on "Olaparib combined with abiraterone in HRR-mutated metastatic hormone-sensitive prostate cancer: a single-arm phase II trial".

Europe PMCOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

Cardiovascular safety of psilocybin in psychiatric practice: a narrative review.

Europe PMCOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

From Small Data to Big Decisions: How Clinical Pharmacology Shapes Rare Disease Development.

Europe PMCOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

Refinement of Operating Characteristics for Model-Based TGI Metrics Decision Support to Ungate a Pivotal Trial in Oncology.

Europe PMCOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

A Bayesian Optimal Adaptive Clinical Trial Design for Sequentially Integrated Therapies.

Europe PMCOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

Safety, Tolerability, Pharmacokinetics, Food Effect of Ribitol, and Its Effect on QTcF in Healthy Adults: First-in-Human, Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled Studies.

Europe PMCOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

Innovative Clinical Pharmacology, Modeling, and Simulation Strategies for Accelerating Rare Disease Drug Development.

Europe PMCOriginal source